MapLight Therapeutics, Inc. (NASDAQ: MPLT) is a Healthcare company (Biotechnology) with a market capitalization of $280M. The Maz Rating grades it against the other companies in its sector.
MapLight Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.57, MapLight Therapeutics, Inc. trades at 0.8x book value, with an EV/EBITDA of 0.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -61.0%, return on invested capital of -61.7% and a free cash flow yield of -60.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 15.00. Over the past 52 weeks the share price ranged from $6.06 to $40.43, with a beta of 3.01.
MapLight Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.